To compare the safety and efficacy of transurethral enucleation of the prostate (TUEP) and transurethral prostate high power holmium laser deburring (HoLEP) for the treatment of benign prostatic hyperplasia in the primary hospital.

250 patients with benign prostatic hyperplasia were retrospectively included in the study, including 156 cases in the TUEP group and 94 cases in the HoLEP group. The clinical data were compared between the two groups.

All operations were successful, no case was transfered to open surgery, and followed up at least 12 monthes. There was no significant difference in the baseline data between the two groups (P>0.05). The hemoglobin changes [(1.2±0.5)g/L vs (2.3±0.8)g/L], postoperative blood biochemical sodium reduction index [(1.9±0.5)mmol/L vs (3.1±1.5)mmol/L], and the postoperative catheter indwelling time [(3.4±0.8)days vs (5.3±1.4)days], hospitalization time [(4.5±1.9)days vs (6.7±2.5)days] in the HoLEP group were smaller or shorter than those in the TUEP group, the differences were statistically significant (P<0.001). The IPSS, RUV, Qmax and QOL of the patients in both groups were improved compared with those before operation (P<0.05). There was no urinary incontinence during the follow-up period and long-term complications were not different between the two groups (6/156 vs 4/94, P>0.05).

TUEP and HoLEP are both safe and effective for the treatment of benign prostatic hyperplasia patients in the primary hospitals, and long-term effects need to be confirmed by further studies.